You have read all your free articles, to continue reading subscribe to read the rest of this content.
Scientists at deCODE genetics in Iceland have discovered rare, protective loss-of-function variants that point to potential drug targets for nonalcoholic fatty liver disease (NAFLD). Last week, the scientists published a large genome-wide association study on nonalcoholic fatty liver disease (NAFAlready a subscriber Login You have read all your free articles,…
Alvotech and DKSH have announced an expansion of their strategic partnership to commercialize six new biosimilar product candidates for the Asian markets. The initial pipeline contains biosimilar candidates addressing multiple therapeutic areas. “We have been delighted to work with DKSH sincAlready a subscriber Login You have read all your free…
Scientists at Icelandic deCODE genetics have found a new biomarker for osteoarthritis, that outperforms previously reported biomarkers and is an independent predictor of disease. In a study published in the medical journal, Arthritis & Rheumatology, the scientists introduced the new biomarkerAlready a subscriber Login You have read all your free…
EpiEndo Pharmaceuticals has received regulatory and ethics approval to commence a Lipopolysaccharide (LPS) challenge clinical trial with its lead molecule EP395. EP395 is an orally available macrolide or ‘Barriolide’ with reduced antimicrobial activity which aims to address the unmet medical Already a subscriber Login You have read all your free…
